<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363803</url>
  </required_header>
  <id_info>
    <org_study_id>201412073</org_study_id>
    <nct_id>NCT02363803</nct_id>
  </id_info>
  <brief_title>Lidocaine for Diabetic Peripheral Neuropathy</brief_title>
  <official_title>Predicting Individual Response to Analgesic Treatment in Painful Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic nerve pain [painful diabetic peripheral neuropathy] is a common medical problem with
      few reliably effective treatments. There is some evidence that sensory testing may help
      determine how individuals will respond to analgesic therapy. In this study, the investigators
      are evaluating the relationship between sensory testing and subject response to lidocaine
      infusion therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic peripheral neuropathy [DPN] is caused by diabetes-related metabolic damage to the
      sensory nervous system. It affects more than 3 million Americans and is leading cause of
      nerve damage-associated pain worldwide. Currently approved drugs such as gabapentin,
      pregabalin, and duloxetine provide pain relief only in 1 out of 4 or 5 people with DPN,
      pointing to a great need to identify effective therapy for these patients. Recent literature
      suggests that certain methods of assessing sensory nerve function in neuropathic pain
      patients may provide prediction to individual analgesic response; however, no
      placebo-controlled studies have been performed with the primary goal of identifying treatment
      response predictors in DPN.

      We propose in this study to examine whether sensory testing to determine mechanical pain
      threshold [MPT] or heat pain threshold [HPT] will predict the subject's response to IV
      lidocaine analgesic therapy. We hypothesize that people with painful DPN who have high MPT or
      HPT are more likely to respond to lidocaine treatment. This is a prospective, double blind,
      placebo-controlled study with the primary objective of determining whether the results from
      the sensory testing predict the response to systemic lidocaine in patients with painful DPN.

      Consented subjects will attend a screening visit and two intervention visits, during which
      they will undergo sensory testing and receive intravenous lidocaine or placebo infusion in a
      cross-over design. At enrollment, each patient will be assigned a study number, which will
      match a previously prepared computer-generated list of randomization numbers to determine the
      sequence of interventions: lidocaine and then placebo, or vice versa. An unblinded research
      nurse coordinator will be assigned to match the study number with randomized treatment
      sequence, and this person will prepare the study medications, which will look identical. This
      research nurse coordinator will not be involved at any stage at patient assessment or data
      analysis. The participants and all other study personnel will be blinded to the treatment
      allocation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">October 17, 2018</completion_date>
  <primary_completion_date type="Actual">October 17, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS)</measure>
    <time_frame>Baseline compared to 60-120 minutes after starting the infusion</time_frame>
    <description>Spontaneous pain will be assessed on numerical rating scale NRS (0= no pain, 10=worst pain imaginable) prior to infusion and then repeatedly for 120 minutes. The outcome measure will use the average of pain intensity measured at timepoints in the 60-120 min range after beginning of infusion. The mean %change in pain (from baseline) will be compared between lidocaine and placebo arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evoked Mechanical and Thermal Sensation at Baseline and 60 Minutes After Infusion Initiation.</measure>
    <time_frame>- 60 minutes (baseline) and + 60 minutes of initiating infusion</time_frame>
    <description>Thermal and mechanical responses will be assessed at baseline and 60 minutes after infusions. Evoked intensities measured on a 0-10 sensory scale, where 5 is normal sensation, a number lower than 5 is reduced sensation and a number higher than 5 is greater sensation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPSI (Neuropathic Pain Symptom Inventory) Descriptors of Pain at Baseline and 60 Min After Infusion</measure>
    <time_frame>Baseline to 60 minutes of initiating infusion</time_frame>
    <description>NPSI pain descriptors will be assessed prior to infusion of placebo and lidocaine (baseline) and again at 60 minutes post-infusion. Descriptors are expressed on a 0-10 scale; 0-minimum (least), and 10 maximum (worst) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spontaneous Pain Intensity as a Function of Baseline MPT</measure>
    <time_frame>baseline to 60-120 minutes after starting the infusion</time_frame>
    <description>Correlation between Mechanical Pain Threshold (MPT in mN) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at 60-120 minutes (averaged) from the study drug infusion. The slopes (Pearson coefficients) of the correlation obtained from lidocaine vs. placebo will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spontaneous Pain Intensity as a Function of Baseline HPT</measure>
    <time_frame>Baseline to 60-120 minutes after starting the infusion</time_frame>
    <description>Correlation between Heat Pain Threshold (HPT in degrees Celsius) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at 60-120 minutes (averaged) from the study drug infusion. The slopes (Pearson coefficients) of the correlation obtained from lidocaine vs. placebo will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Diabetes</condition>
  <condition>Peripheral Neuropathy</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Normal saline infusion then lidocaine infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine infusion, then normal saline infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.</description>
    <arm_group_label>Lidocaine infusion, then normal saline infusion</arm_group_label>
    <arm_group_label>Normal saline infusion then lidocaine infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline, approved for hypovolemia, and homeostasis.</description>
    <arm_group_label>Lidocaine infusion, then normal saline infusion</arm_group_label>
    <arm_group_label>Normal saline infusion then lidocaine infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18;

          2. Diagnosis of Diabetes Mellitus (Fasting Plasma Glucose &gt; 126 mg/dL and/or HbA1C
             &gt;6.5%);

          3. Distal symmetric pain in lower extremities with duration of more than 3 months;

          4. Presence of either numbness or at least 1 sensory disturbance (increased or decreased
             sensitivity) in the feet.

          5. Spontaneous pain with intensity of ≥ 4 on 0-10 Numerical Rating Scale (NRS).

        Exclusion Criteria:

          1. Not giving consent to participate in the study;

          2. Unable to complete self-report pain questionnaire;

          3. History of moderate to severe renal or liver failure;

          4. History of other central or peripheral neurologic disorders;

          5. History of cardiac arrhythmias;

          6. Contraindication to intravenous lidocaine;

          7. Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Haroutounian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, WUSTL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine/Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <results_first_submitted>October 11, 2019</results_first_submitted>
  <results_first_submitted_qc>October 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>simon.haroutounian</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02363803/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant only received lidocaine infusion and did not return to receive saline infusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Saline First, Then Lidocaine</title>
          <description>Intravenous infusion of normal saline (placebo) over a 40 minute period (Period 1). Intravenous infusion of lidocaine 5mg/kg IBW over a 40 min period (Period 2)</description>
        </group>
        <group group_id="P2">
          <title>Lidocaine First, Then Saline</title>
          <description>Intravenous infusion of lidocaine 5mg/kg IBW over a 40 min period (Period 1). Intravenous infusion of normal saline (placebo) over a 40 minute period (Period 2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16">One participant did not return for Period 2 treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline First, Then Lidocaine</title>
          <description>Intravenous infusion of normal saline (placebo) over a 40 minute period (Period 1). Intravenous infusion of lidocaine 5mg/kg IBW over a 40 min period (Period 2)</description>
        </group>
        <group group_id="B2">
          <title>Lidocaine First, Then Saline</title>
          <description>Intravenous infusion of lidocaine 5mg/kg IBW over a 40 min period (Period 1). Intravenous infusion of normal saline (placebo) over a 40 minute period (Period 2).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="12"/>
                    <measurement group_id="B2" value="56" spread="10"/>
                    <measurement group_id="B3" value="57" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average pain intensity within the past week</title>
          <description>Average pain within the past week at study intake, assessed on a 0-10 Numerical Rating Scale, where 0 is no pain, and 10 is worst pain imaginable</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="B2" value="6.5" lower_limit="5.5" upper_limit="7"/>
                    <measurement group_id="B3" value="6.25" lower_limit="5" upper_limit="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS)</title>
        <description>Spontaneous pain will be assessed on numerical rating scale NRS (0= no pain, 10=worst pain imaginable) prior to infusion and then repeatedly for 120 minutes. The outcome measure will use the average of pain intensity measured at timepoints in the 60-120 min range after beginning of infusion. The mean %change in pain (from baseline) will be compared between lidocaine and placebo arms.</description>
        <time_frame>Baseline compared to 60-120 minutes after starting the infusion</time_frame>
        <population>Participants who completed both infusions and had non-zero pain scores at the start of each infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline Infusion</title>
            <description>Intravenous infusion of normal saline over a 40 minute period.
Placebo: Normal saline, approved for hypovolemia, and homeostasis.</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Infusion</title>
            <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
lidocaine: lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS)</title>
          <description>Spontaneous pain will be assessed on numerical rating scale NRS (0= no pain, 10=worst pain imaginable) prior to infusion and then repeatedly for 120 minutes. The outcome measure will use the average of pain intensity measured at timepoints in the 60-120 min range after beginning of infusion. The mean %change in pain (from baseline) will be compared between lidocaine and placebo arms.</description>
          <population>Participants who completed both infusions and had non-zero pain scores at the start of each infusion.</population>
          <units>percentage of pain change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="46"/>
                    <measurement group_id="O2" value="51" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evoked Mechanical and Thermal Sensation at Baseline and 60 Minutes After Infusion Initiation.</title>
        <description>Thermal and mechanical responses will be assessed at baseline and 60 minutes after infusions. Evoked intensities measured on a 0-10 sensory scale, where 5 is normal sensation, a number lower than 5 is reduced sensation and a number higher than 5 is greater sensation.</description>
        <time_frame>- 60 minutes (baseline) and + 60 minutes of initiating infusion</time_frame>
        <population>Participants who received both lidocaine and normal saline infusions were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline: Prior to Infusion</title>
            <description>Intravenous infusion of normal saline over a 40 minute period.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline: 60 Minutes After Infusion Initiation</title>
            <description>Intravenous infusion of normal saline over a 40 minute period.</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine: Prior to Infusion</title>
            <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.</description>
          </group>
          <group group_id="O4">
            <title>Lidocaine: 60 Minutes After Infusion Initiation</title>
            <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Evoked Mechanical and Thermal Sensation at Baseline and 60 Minutes After Infusion Initiation.</title>
          <description>Thermal and mechanical responses will be assessed at baseline and 60 minutes after infusions. Evoked intensities measured on a 0-10 sensory scale, where 5 is normal sensation, a number lower than 5 is reduced sensation and a number higher than 5 is greater sensation.</description>
          <population>Participants who received both lidocaine and normal saline infusions were analyzed.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cold intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O4" value="3" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heat intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brush intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O4" value="4" lower_limit="1.5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pinprick intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1.5" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="5.5"/>
                    <measurement group_id="O3" value="4" lower_limit="1.5" upper_limit="6"/>
                    <measurement group_id="O4" value="3" lower_limit="1" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NPSI (Neuropathic Pain Symptom Inventory) Descriptors of Pain at Baseline and 60 Min After Infusion</title>
        <description>NPSI pain descriptors will be assessed prior to infusion of placebo and lidocaine (baseline) and again at 60 minutes post-infusion. Descriptors are expressed on a 0-10 scale; 0-minimum (least), and 10 maximum (worst) score.</description>
        <time_frame>Baseline to 60 minutes of initiating infusion</time_frame>
        <population>Participants who received both lidocaine and normal saline infusions analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline: Prior to Infusion</title>
            <description>Intravenous infusion of normal saline over a 40 minute period.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline: 60 Minutes After Infusion Initiation</title>
            <description>Intravenous infusion of normal saline over a 40 minute period.</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine: Prior to Infusion</title>
            <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.</description>
          </group>
          <group group_id="O4">
            <title>Lidocaine: 60 Minutes After Infusion Initiation</title>
            <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>NPSI (Neuropathic Pain Symptom Inventory) Descriptors of Pain at Baseline and 60 Min After Infusion</title>
          <description>NPSI pain descriptors will be assessed prior to infusion of placebo and lidocaine (baseline) and again at 60 minutes post-infusion. Descriptors are expressed on a 0-10 scale; 0-minimum (least), and 10 maximum (worst) score.</description>
          <population>Participants who received both lidocaine and normal saline infusions analyzed.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Does your pain feel like burning?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Does your pain feel like squeezing?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Does your pain feel like electric shocks?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Does your pain feel like stabbing?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Do you feel pins and needles?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="5.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="4" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Do you feel tingling?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="4" lower_limit="1.5" upper_limit="6"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spontaneous Pain Intensity as a Function of Baseline MPT</title>
        <description>Correlation between Mechanical Pain Threshold (MPT in mN) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at 60-120 minutes (averaged) from the study drug infusion. The slopes (Pearson coefficients) of the correlation obtained from lidocaine vs. placebo will be compared.</description>
        <time_frame>baseline to 60-120 minutes after starting the infusion</time_frame>
        <population>Participants who completed both infusions and had non-zero pain scores at the start of each infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline Infusion</title>
            <description>Intravenous infusion of normal saline over a 40 minute period.</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Infusion</title>
            <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spontaneous Pain Intensity as a Function of Baseline MPT</title>
          <description>Correlation between Mechanical Pain Threshold (MPT in mN) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at 60-120 minutes (averaged) from the study drug infusion. The slopes (Pearson coefficients) of the correlation obtained from lidocaine vs. placebo will be compared.</description>
          <population>Participants who completed both infusions and had non-zero pain scores at the start of each infusion.</population>
          <units>Pearson coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".249" lower_limit="-.098" upper_limit=".538"/>
                    <measurement group_id="O2" value=".063" lower_limit="-.308" upper_limit="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spontaneous Pain Intensity as a Function of Baseline HPT</title>
        <description>Correlation between Heat Pain Threshold (HPT in degrees Celsius) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at 60-120 minutes (averaged) from the study drug infusion. The slopes (Pearson coefficients) of the correlation obtained from lidocaine vs. placebo will be compared.</description>
        <time_frame>Baseline to 60-120 minutes after starting the infusion</time_frame>
        <population>Participants who completed both infusions and had non-zero pain scores at the start of each infusion. Two additional participants excluded as they could not sense heat on test site.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline Infusion</title>
            <description>Intravenous infusion of normal saline over a 40 minute period.</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Infusion</title>
            <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spontaneous Pain Intensity as a Function of Baseline HPT</title>
          <description>Correlation between Heat Pain Threshold (HPT in degrees Celsius) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at 60-120 minutes (averaged) from the study drug infusion. The slopes (Pearson coefficients) of the correlation obtained from lidocaine vs. placebo will be compared.</description>
          <population>Participants who completed both infusions and had non-zero pain scores at the start of each infusion. Two additional participants excluded as they could not sense heat on test site.</population>
          <units>Pearson coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".023" lower_limit="-.372" upper_limit=".493"/>
                    <measurement group_id="O2" value="-.151" lower_limit="-.467" upper_limit=".206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-120 minutes after infusion initiation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Saline Infusion</title>
          <description>Intravenous infusion of normal saline over a 40 minute period.
Placebo: Normal saline, approved for hypovolemia, and homeostasis.</description>
        </group>
        <group group_id="E2">
          <title>Lidocaine Infusion</title>
          <description>Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
lidocaine: lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Perioral numbness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Slurred speech</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Simon Haroutounian</name_or_title>
      <organization>Washington University in St. Louis</organization>
      <phone>3143622628</phone>
      <email>sharout@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

